This research study is designed to establish normative database and reliability of ImPACT for adolescents and adults ages 12 through 80 to expand the use of devices to include touchscreen.
- Study Type: Interventional
- Study Design
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Primary Purpose: Screening
- Masking: None (Open Label)
- Study Primary Completion Date: June 1, 2023
This research study is designed to establish normative database and reliability of ImPACT for adolescents and adults ages 12 through 80 to expand the use of devices to include touchscreen. Enrollment will be 900 participants.
- Device: Normative
- ImPACT will be administered at baseline testing
- Device: Reliability
- ImPACT will be administered again within 60 days of baseline test
Arms, Groups and Cohorts
- Other: Normative
- ImPACT will be administered to participant’s for a baseline test.
- Other: Reliability
- ImPACT will be administered to participant’s within 60 days of baseline test.
Clinical Trial Outcome Measures
- Time Frame: 12 months
- ImPACT Touchscreen performs within normal parameters of ImPACT Online
- Time Frame: Baseline test will be administered at enrollment and re-test will be administered within 60 days of baseline test.
- Reliability will be established through a test/re-test. ImPACT Touchscreen will be administered at 2 time points to establish results should be stable over time.
Participating in This Clinical Trial
1. Age 12-80 2. Primary English speaking or fluent in English Exclusion Criteria:
1. Documentation of a known special education diagnosis other than a 504 designation. 2. History of concussion less than 6 months to the study participation 3. Known physical (e.g., visual impairment not fixable by usual means, such as glasses) or psychological impairment (ADHD, LDD, etc.) that would affect their ability to perform the test.
Gender Eligibility: All
Minimum Age: 12 Years
Maximum Age: 80 Years
Are Healthy Volunteers Accepted: Accepts Healthy Volunteers
- Lead Sponsor
- ImPACT Applications, Inc.
- Provider of Information About this Clinical Study
- Overall Contact(s)
- Jane Luce, 7245446846, firstname.lastname@example.org
Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.